Adaptimmune Annual report pursuant to Section 13 and 15(d)

Other current assets

12 Months Ended

Dec. 31, 2022

Note 5 — Other current assets

Other current assets consisted of the following (in thousands):


	December 31,		December 31,
	2022		2021
Research and development credits receivable	$	30,162	$	30,773
Prepayments		9,472		9,043
Clinical materials		1,279		746
VAT receivable		490		2,482
Other current assets		1,927		2,082
	$	43,330	$	45,126